Tikvah Therapeutics Raises $10 Million Gross Proceeds in Private Financing

ATLANTA, July 12, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company that focuses on novel therapeutic treatments for diseases of the central nervous system, including neurology and psychiatry disorders, announced today it has completed a private financing with gross proceeds of $10 million in a convertible note financing. Paramount BioCapital, Inc. served as the placement agent. Tikvah Therapeutics was founded by Paramount BioSciences, LLC.